PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786974
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786974
The home infusion therapy market size is expected to reach USD 83.31 billion by 2034, according to a new study by Polaris Market Research. The report "Home Infusion Therapy Market Size, Share, Trend, Industry Analysis Report By Type (Product, Service), By Application (Anti-infective, Endocrinology, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition), By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The home infusion therapy market refers to the administration of medications through intravenous or subcutaneous routes in a patient's home setting, rather than in hospitals or infusion centers. This approach supports patient convenience, lowers healthcare costs, and reduces hospital-acquired infection risks. The increasing prevalence of chronic diseases such as cancer, immune deficiencies, and gastrointestinal disorders has accelerated demand for home-based treatment alternatives. Payers and healthcare systems are pushing for outpatient and home care models to curb rising inpatient costs, reinforcing adoption of infusion services delivered outside traditional clinical settings. The market growth is also supported by the development of compact, user-friendly infusion pumps and digital health tools that enable remote monitoring and virtual care integration.
Ongoing advancements in biologics and specialty drugs tailored for chronic disease management boost the need for reliable home infusion protocols. Physician acceptance and reimbursement clarity have significantly improved, enabling broader patient eligibility. Pharmaceutical companies and service providers are forming value-based partnerships to bundle drug delivery with ongoing care management, enhancing patient adherence and therapeutic outcomes. The home infusion therapy market is witnessing increased focus on service personalization, leveraging patient-centric logistics and education.
Opportunities exist in expanding therapeutic areas, including hormonal therapies, pain management, and rare disease treatments, where infusion is clinically required and frequent hospital visits are burdensome. The integration of telehealth and automated documentation systems is transforming operational efficiency, allowing providers to manage high patient volumes while maintaining care quality. Home infusion continues to evolve as a key component in long-term care strategies and decentralized healthcare delivery.
By type, the service segment accounted for ~72% of the revenue share in 2024, due to the growing need for skilled nursing, pharmacy support, and on-site administration expertise in home settings.
Based on application, the anti-infective segment accounted for the largest revenue share in 2024, due to the widespread use of intravenous antibiotics to treat infections such as osteomyelitis, cellulitis, and endocarditis in outpatient settings.
North America accounted for ~57% share of the home infusion therapy market revenue in 2024 due to strong healthcare infrastructure, widespread insurance coverage, and an aging population requiring long-term care.
The Asia Pacific market is expected to grow significantly from 2025 to 2034 due to rising healthcare awareness, urbanization, and efforts to decentralize medical care.
A few global key players include Amedisys, Inc.; B. Braun SE; Baxter; BD; CareCentrix, Inc.; Coram LLC.; Fresenius Kabi AG; ICU Medical, Inc.; JMS Co. Ltd.; Moog Inc.; Option Care Health, Inc.; PharMerica Corporation; and Terumo Corporation.
Polaris Market Research has segmented the home infusion therapy market on the basis of type, application, and region:
By Type Outlook (Revenue, USD Billion, 2020-2034)
Product
Infusion Pumps
Elastomeric
Electromechanical
Gravity
Others
Intravenous Sets
IV Cannulas
Needleless Connectors
Services
By Application Outlook (Revenue, USD Billion, 2020-2034)
Anti-Infective
Endocrinology
Diabetes
Others
Hydration Therapy
Chemotherapy
Enteral Nutrition
Parenteral Nutrition
Specialty Pharmaceuticals
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa